BioPorto Expands U.S. Validation Study for AKI Test After FDA Feedback
Event summary
- BioPorto to initiate a larger U.S. Adult Urine NGAL Validation Study with ~900 patients, up from ~500, following FDA feedback.
- FDA clearance for ProNephro AKI™ now expected mid-2028, delayed from earlier projections.
- Additional study costs of ~DKK 20 million (70% increase), pushing cash flow positivity to second half of 2028.
- CEO Carsten Buhl emphasizes FDA alignment as a milestone for U.S. adult Acute Kidney Injury market entry.
The big picture
BioPorto’s expanded validation study reflects the FDA’s demand for robust performance claims in the U.S. adult population, a critical step for entering a market with significant unmet medical needs. The delay and added costs highlight the regulatory hurdles in diagnostic approvals, but alignment with FDA sets a stronger foundation for long-term commercial success. The shift in cash flow positivity underscores the financial trade-offs of regulatory compliance in scaling diagnostic products.
What we're watching
- Regulatory Alignment
- How FDA’s feedback on study design will impact BioPorto’s 510(k) submission timeline and approval odds.
- Financial Flexibility
- Whether BioPorto can bridge additional cash flow needs through operational efficiencies or credit facilities.
- Market Timing
- The pace at which BioPorto can capitalize on the U.S. adult Acute Kidney Injury market post-clearance.